Susceptibility, Mycobacterium tuberculosis Complex, Pyrazinamide, Varies
Use
Susceptibility testing of Mycobacterium tuberculosis complex isolates is essential for determining the appropriate antibiotic therapy. Pyrazinamide (PZA) is one of the first-line medications used in the treatment of tuberculosis, in combination with other antimycobacterial agents including isoniazid, rifampin, and ethambutol. Detecting resistance to PZA helps guide treatment decisions and manage patient outcomes effectively. Variants in the pncA gene are a major cause of pyrazinamide resistance, making this test critical in identifying resistant isolates.
Special Instructions
This test is conducted using FDA-cleared platforms, either BD MGIT 960 or VersaTREK systems. Specimens should be sent in compliance with infectious shipping guidelines, and a microbiology test request form should accompany the specimen if not ordered electronically. Organism identification is required for the test.
Limitations
Some Mycobacterium tuberculosis complex isolates might display falsely resistant results to PZA in broth testing. Such findings prompt automatic confirmation with sequencing of the pncA gene. Absence of pncA gene mutations does not rule out resistance since other genes may play a role. The test is not applicable for Mycobacterium bovis or Myocobacterium bovis bacille Calmette-Guerin (BCG) as they are inherently resistant to pyrazinamide.
FDA ApprovedNew York Approved
Methodology
Culture-based
Biomarkers
LOINC Codes
- 56026-8
- 56026-8
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Isolate
Minimum Volume
Not provided
Container
Middlebrook 7H10 agar slant
Collection Instructions
Organism should be in pure culture, actively growing.
Causes for Rejection
Agar plate